Oral Cancer News and Research

RSS

Oral cancer is the sixth most common type of cancer worldwide and in the U.S., one person dies every hour from the disease. According to American Cancer Society data, nearly as many women will be diagnosed with oral cancer as with cervical cancer this year. The key to reducing the impact of this disease is early detection.

New Aspen Dental office to open in Murfreesboro, TN on June 5

A new Aspen Dental office is opening in Murfreesboro, TN on Thursday, June 5. Located at 2711 Medical Center Parkway, the conveniently located practice will provide dental services that range from dentures and preventive care to general dentistry and restoration.

9 May 2014

New Aspen Dental office to open in St. Augustine, FL

A new Aspen Dental office is opening in St. Augustine, FL on Thursday, June 5. Located at 1747 US Highway 1 South, the conveniently located practice will provide dental services that range from dentures and preventive care to general dentistry and restoration.

8 May 2014

No increased HPV-linked oral cancer risk for long-term partners, says study

Partners of patients diagnosed with human papilloma virus (HPV)-positive oropharyngeal cancer (OPC) were no more likely to test positive for oral HPV infection than people in the general population, according to a study published in the April 28 online edition of the Journal of Clinical Oncology.

2 May 2014

Zenalux, RPCI collaborate to enhance Zenascope system to detect oral cancers at an early stage

Zenalux Biomedical, Inc., a leader in biophotonic diagnostics, is working with Roswell Park Cancer Institute to further enhance its flagship Zenascope™ product by adding a high-resolution camera to the system.

25 Apr 2014

New Aspen Dental office opens in Pickerington, OH

A new Aspen Dental office is opening in Pickerington, OH on Thursday, April 17. Located at 10705 Blacklick Eastern Rd 100, the conveniently located practice will provide dental services that range from dentures and preventive care to general dentistry and restoration.

21 Apr 2014

Research sheds new light on the development of HPV-associated cancer

It's long been known that certain strains of human papillomavirus (HPV) cause cancer. Now, researchers at The Ohio State University have determined a new way that HPV might spark cancer development - by disrupting the human DNA sequence with repeating loops when the virus is inserted into host-cell DNA as it replicates.

17 Apr 2014

Millennium Medical Devices inks another network selling agreement

Millennium HealthCare Inc. today announced that its subsidiary, Millennium Medical Devices LLC, has signed yet another network selling agreement. This agreement was signed with a US based healthcare organization for the use of Millennium's medical devices in 400 of the organization's locations. This agreement includes an average monthly minimum use of 350 units per device, per location.

9 Apr 2014

People urged to undergo oral cancer screenings as part of Oral Cancer Awareness Month

Oral and oropharyngeal cancer (cancer of the mouth and upper throat) collectively kill nearly one person every hour of every day of the year.

27 Mar 2014

Oral cancer drug improves outcomes in women with resistant gynecologic cancers

An oral cancer drug improves outcomes while minimizing side effects in women with gynecologic cancers who carry a BRCA mutation and whose disease is not responding to other therapies, suggests preliminary research.

26 Mar 2014

Vigilant announces completion of $2 million oversubscribed Series A financing

Vigilant Biosciences, Inc., developer of the "rinse and spit" test for assessing early risk of oral cancer, today announced the successful completion of a $2.0 million, oversubscribed Series A financing. The company received $2.3 million in total proceeds, including a $300,000 loan from the Florida Institute for the Commercialization of Public Research Seed Capital Acceleration Program.

25 Mar 2014

Real-time cervical cancer diagnostics: an interview with Sameer Kothari, Chief Executive of Zilico

Cervical cancer diagnosis is a two-step process. In developed countries, women are invited for a smear test which mainly uses LBC (liquid-based cytology), where a sample of cells are taken from the cervix and sent to a cytopathology lab for analysis.

From Zilico 19 Mar 2014

Simple protein test useful in predicting survival chances for patients with head-and-neck cancer

Scientists from The University of Manchester - part of the Manchester Cancer Research Centre - used a simple protein test that could prove more useful in predicting survival chances for patients with head-and-neck cancer compared to existing methods.

24 Jan 2014

Number of cancer stem cells in tumor might inaccurately estimate tumor's recurrence or progression

New research from The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) suggests that it may be the quality of cancer stem cells rather than their quantity that leads to better survival in certain patients with oral cancer.

23 Jan 2014

New Aspen Dental office to be opened in Jacksonville, FL

A new Aspen Dental office is opening in Jacksonville, FL on Thursday, January 30. Located at 11806 Atlantic Blvd, the conveniently located practice will provide dental services that range from dentures and preventive care to general dentistry and restoration.

18 Jan 2014

Navidea Biopharmaceuticals, GMST sign distribution agreement for Lymphoseek Injection in Taiwan

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today it has entered into a distribution agreement for Lymphoseek (technetium Tc 99m tilmanocept) Injection in Taiwan with Global Medical Solutions Taiwan, Ltd., a leading in-country distributor of nuclear medicine and diagnostic imaging products.

7 Jan 2014

Navidea seeks FDA approval for marketing Lymphoseek Injection for SLN detection

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today that it has submitted a Supplemental New Drug Application with the U.S. Food and Drug Administration seeking approval for the marketing and sale of Lymphoseek (technetium 99m tilmanocept) Injection for sentinel lymph node detection in patients with head and neck cancer, an indication for which Lymphoseek was also granted Fast Track designation earlier this month.

17 Dec 2013

RT Oncology and Express Scripts enter into pharmaceutical drug distribution agreement

RT Oncology Services Corporation ("RainTree"), the nation's leading community oncology alliance, and Express Scripts (NASDAQ: ESRX), the nation's leading pharmacy benefit manager, today announced that they have entered into an exclusive, three-year pharmaceutical drug distribution agreement.

16 Dec 2013

Navidea receives Fast Track designation for Lymphoseek injection

Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today that the US Food and Drug Administration (FDA) has granted Fast Track designation to Lymphoseek® (technetium 99m tilmanocept) Injection for sentinel lymph node detection in patients with head and neck cancer.

11 Dec 2013

UCSF investigator receives $89 M grant to research on anal cancer in people with HIV

A UC San Francisco investigator has won an eight-year grant from the National Cancer Institute for a major investigation into anal cancer, a debilitating and sometimes fatal disease largely concentrated among people with HIV.

25 Nov 2013

Incidence of oropharyngeal cancer on the rise

NCI scientists report that the incidence of oropharyngeal cancer significantly increased during the period 1983-2002 among people in countries that are economically developed.

22 Nov 2013